August 4, 2016
Comments in support of CMS Proposal for HBV Screening.
January 11, 2016
Letter to the Food and Drug Administration regarding recent regulations banning minors from using sunlamp products, and requiring adults visiting an indoor tanning facility to be properly informed of the risks involved.
February 27, 2015
Letter to the Office of Management and Budget and Congress regarding President Obama’s FY16 budget proposal. Specifically, the letter opposes cuts to the Centers for Disease Control and Prevention’s (CDC) cancer screening programs.
January 12, 2015
Letter to Sylvia Burwell (Secretary, U.S. Department of Health and Human Services) regarding the Draft 2016 Letter to Issuers in the Federally-Facilitated Marketplaces
December 10, 2014
Letter to Tamara Syrek Jensen (Director, Coverage and Analysis Group, Center for Medicare and Medicaid Services) regarding the proposed National Coverage Determination for Lung Cancer Screening with Low Dose Computed Tomography (CAG-00439N).
August 15, 2014
Letter to Tamara Syrek Jensen (Director, Coverage and Analysis Group, Center for Medicare and Medicaid Services) regarding the proposed decision memorandum for screening for colorectal cancer using Cologuard™—A Multitarget Stool DNA Test
August 4, 2014
Letter to Mitchell Zeller (Director, Center for Tobacco Products, U.S. Food and Drug Administration) regarding FDA-2014-N-0189, deeming tobacco products to be subject to the Federal Food, Drug, and Cosmetic Act.
The Prevent Cancer Foundation strongly urges all Members of Congress, particularly those on the Senate and House Committees on Appropriations, to support funding for the National Institutes of Health (NIH), National Cancer Institute (NCI) and Centers for Disease Control and Prevention (CDC) Division of Cancer Prevention and Control (DCPC) in the FY 2015 Labor-HHS-Education appropriations bill.
February 24, 2014
Letter to Marilyn Tavenner (Administrator, Centers for Medicare and Medicaid Services) regarding CMS-4159-P, Contract Year
2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs (“protected